Heart Failure With Preserved Ejection Fraction: Time for a Reset

Affiliations

Comment

Katherine A A Clark et al. JAMA. 2020.

. 2020 Oct 20;324(15):1506-1508.

doi: 10.1001/jama.2020.15566.

¹ Section of Cardiovascular Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.

No abstract available

Comment on

Effect of Vericiguat vs Placebo on Quality of Life in Patients With Heart Failure and Preserved Ejection Fraction: The VITALITY-HFpEF Randomized Clinical Trial.
Armstrong PW, Lam CSP, Anstrom KJ, Ezekowitz J, Hernandez AF, O'Connor CM, Pieske B, Ponikowski P, Shah SJ, Solomon SD, Voors AA, She L, Vlajnic V, Carvalho F, Bamber L, Blaustein RO, Roessig L, Butler J; VITALITY-HFpEF Study Group. Armstrong PW, et al. JAMA. 2020 Oct 20;324(15):1512-1521. doi: 10.1001/jama.2020.15922. JAMA. 2020. PMID: 33079152 Free PMC article. Clinical Trial.
Effect of Praliciguat on Peak Rate of Oxygen Consumption in Patients With Heart Failure With Preserved Ejection Fraction: The CAPACITY HFpEF Randomized Clinical Trial.
Udelson JE, Lewis GD, Shah SJ, Zile MR, Redfield MM, Burnett J Jr, Parker J, Seferovic JP, Wilson P, Mittleman RS, Profy AT, Konstam MA. Udelson JE, et al. JAMA. 2020 Oct 20;324(15):1522-1531. doi: 10.1001/jama.2020.16641. JAMA. 2020. PMID: 33079154 Free PMC article. Clinical Trial.